AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
18.6.2020 03:00:00 EEST | Business Wire | Press release
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Contact information
Fred Kim
734-516-8732
fredkim@aribiousa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Forrester Opens Nominations For Its 2026 B2B Awards In EMEA17.6.2026 11:42:00 EEST | Press release
Forrester (Nasdaq: FORR) today opened nominations for its 2026 B2B Return On Integration Honours and B2B Programmes Of The Year Awards for Europe, the Middle East, and Africa (EMEA). The awards recognize organisations that are driving measurable business impact through customer-obsessed growth strategies. Winners will be honoured at Forrester’s B2B Forum EMEA, taking place in London, 28–29 September 2026. The B2B Return On Integration (ROI) Honours celebrate organisations that have successfully aligned marketing, revenue, product, and customer functions to deliver measurable outcomes and drive enterprisewide performance. The B2B Programmes Of The Year (POY) Awards recognise standout functional initiatives across areas including marketing, revenue, customer engagement, and product that demonstrate innovation and measurable results. “Today’s B2B leaders are under pressure to deliver growth in increasingly complex and evolving environments,” said Paul Ferron, VP and research director at F
Klarna Partners With Bolt to Grow ‘Pay in Full’ for Rides and Scooters17.6.2026 11:20:00 EEST | Press release
Klarna, the global digital bank and payments provider, has partnered with Bolt, the European shared mobility platform, to bring Klarna's payment options directly into the Bolt app. Across Sweden, Germany, Finland and Norway, users can now pay for car rides and scooters with Klarna, with car rentals also available in Germany. The integration is built on tokenised payments, allowing users to pay through their stored credentials without re-entering details for each trip. In all four markets, customers can choose to pay in full or pay monthly with Klarna. The rollout is already underway, with full availability across all four markets expected by the end of June 2026. The partnership brings together two of Europe's largest consumer platforms: Bolt serves more than 200 million customers across over 50 countries, while Klarna has over 119 million active users worldwide. For Klarna, it deepens a growing presence in everyday, high-frequency spending, placing the company at the point of payment
Ohmium and Hynfra Sign Master Cooperation Agreement to Advance Large-Scale Green Hydrogen Projects in the Middle East and Africa17.6.2026 11:17:00 EEST | Press release
Ohmium International Inc., a leading manufacturer of high-efficiency, modular Proton Exchange Membrane (PEM) electrolyzers, and Hynfra P.S.A., a prominent green hydrogen and green ammonia project developer, today announced the signing of a master cooperation agreement to advance green hydrogen projects in Mauritania, Jordan, and Oman. The cooperation agreement covers the projects’ Front-End Engineering and Design (FEED) stage and establishes the framework for ongoing collaboration. Ohmium also will provide technical support and PEM electrolyzer expertise throughout the FEED and development stages for the three hydrogen projects mentioned. These projects are designed to produce green hydrogen for green ammonia applications, advancing energy security and long-term resilience in host countries by building domestically sourced clean energy capacity and reducing dependence on imported fossil fuels, while also supplying RFNBO-compliant green ammonia for export, including to European markets.
ID UNLIMITED Strengthens European Platform With Acquisition of Denmark’s Jet Sport17.6.2026 11:00:00 EEST | Press release
ID UNLIMITED, a European leader in premium equipment personalisation and embellishment services for sports clubs, leagues and global sports brands, has signed an agreement to acquire Jetsport A/S (“Jet Sport”), a provider of personalisation and customisation services headquartered in Viborg, Denmark, specialised in sportswear and workwear. Jet Sport marks the first acquisition under ID UNLIMITED's international expansion strategy since partnering with TowerBrook Capital Partners in April this year. The transaction is expected to close by the end of June 2026, subject to customary conditions. Founded in 1971, Jet Sport is a family-owned business with over five decades of experience in textile embellishment. The company serves sports clubs, sporting goods retailers, workwear suppliers and industrial clients, providing high-quality screen prints, heat transfers and embroideries with approximately 140 employees. Jet Sport has built a reputation for quality, fast turnaround and technical in
Reply Achieves the AWS Business Value Realization Competency17.6.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY] announced today that it has achieved the Amazon Web Services (AWS) Business Value Realization Competency. This specialization recognizes Reply as an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617874809/en/ Reply achieves the Amazon Web Services (AWS) Business Value Realization Competency that recognizes an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. Achieving the AWS Business Value Realization Competency differentiates Reply as an AWS Partner that excels at helping customers define, measure, and achieve business outcomes from their cloud and AI investments. It signals to customers that a Partner has the commitment, trained and certified teams, and a proven track record of delivering measurable outcomes, not just technical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom